https://www.selleckchem.com/pr....oducts/talabostat.ht
s and/or reconsider the appropriateness of FHS-7 as a primary care risk-stratification tool. On balance, the benefits and harms of mammography screening put systematic screening for average-risk women into question. Since screening decisions frequently occur in primary care, it is important to understand what family physicians think of the evidence on mammography screening, and how they intend to use this information in practice. Using a cross-sectional design, we obtained data from a group of physician participants who rated the dai
Like
Comment
Share
